J. Alzheimers Dis. [JOURNAL]
Sun
200 papers
Engendering trustworthiness in the community: Strategies for researchers.
Bouges S, Alagoz E, Gutierrez-Meza D … +18 more , Noell D, Hollnagel F, Oby A, Flowers-Benton S, Fischer B, Gooding DC, Anthony RL, Carter FP, Ennis GE, Van Hulle C, Zuelsdorff M, Lambrou NH, James TT, Umucu E, Carlsson CM, Asthana S, Gleason CE, Passmore SR
J Alzheimers Dis · 2026 Jun · PMID 42360038 · Publisher ↗
BackgroundDespite significant advances in Alzheimer's disease treatment, underrepresentation of ethnoracialized groups in clinical trials limit the generalizability of study findings. Though mistrust in health care resea...
BackgroundDespite significant advances in Alzheimer's disease treatment, underrepresentation of ethnoracialized groups in clinical trials limit the generalizability of study findings. Though mistrust in health care research is a known barrier to clinical trial participation, methods are needed to quantitate this multidimensional subjective term. This study investigated how Black participants view trustworthiness.ObjectiveTo provide an overview of participants' views of a trustworthy study design and investigator.MethodsThis qualitative study utilized focus group discussions with Black participants 45 years and older. Transcripts were coded by three researchers by means of content analysis. After central categories were identified using concept mapping, we constructed a conceptual model of trust to reflect participants' views of trustworthiness.ResultsParticipants self-identified as Black, were a mean age of 62, and predominantly female (80%). Focus group analysis revealed that a trustworthy study design and its impact as well as a trustworthy investigator were central categories of trustworthiness. Comprehensive study outlines, detailed information on the disease being studied, and sharing of study results improved participants' willingness to be involved in studies. Participants also value researchers who are scientifically and culturally competent, knowledgeable, attentive and who engage in education and sharing comprehensive resources on diseases impacting vulnerable populations.ConclusionsThese findings suggest that trustworthy features of the study design and researcher characteristics can provide a foothold to build trust with a population whose mistrust of research is well-documented. Further research on trustworthiness is necessary to develop tools to create a framework for building a trustworthy research environment.
Language as a central axis for studying Alzheimer's disease: From pathogenesis and clinical practice to scientific theory.
Ivanova O
J Alzheimers Dis · 2026 Jun · PMID 42360037 · Publisher ↗
In recent years, language has emerged as a central focus of research on Alzheimer's disease (AD), the most prevalent cause of dementia worldwide. Linguistic change is now increasingly regarded not only as a core symptom...
In recent years, language has emerged as a central focus of research on Alzheimer's disease (AD), the most prevalent cause of dementia worldwide. Linguistic change is now increasingly regarded not only as a core symptom of AD, but also as a potential early marker of disease onset and progression. In this context, Teruo Yokoi offers a timely and valuable contribution by proposing a systematic account of how, and why, language is preferentially affected in AD. In this brief commentary, I examine the significance of their proposal and advance additional reflections on the role of language in the early diagnosis of AD.
Perceptual-phase eye-tracking during figure copying is associated with amyloid-β PET positivity in mild cognitive impairment.
Wang Q, Bai Y, Shin BS … +1 more , Kim KW
J Alzheimers Dis · 2026 Jun · PMID 42340330 · Publisher ↗
BackgroundAmyloid-β (Aβ) pathology is a core feature of Alzheimer's disease (AD) and may be present in mild cognitive impairment (MCI). Accessible, non-invasive markers of early Aβ-related cognitive change are needed.Obj...
BackgroundAmyloid-β (Aβ) pathology is a core feature of Alzheimer's disease (AD) and may be present in mild cognitive impairment (MCI). Accessible, non-invasive markers of early Aβ-related cognitive change are needed.ObjectiveTo investigate whether perceptual-phase eye-tracking metrics during figure copying are associated with Aβ-PET positivity in MCI.MethodsIn this cross-sectional study, 59 patients with MCI underwent F-flutemetamol PET and were classified as Aβ-PET positive (n = 34) or Aβ-PET negative (n = 25). Participants completed a simplified Rey-Osterrieth Complex Figure Test while wearing eye-tracking glasses. The display was then divided into perceptual and working areas of interest (AOIs), and metrics were extracted for each AOI. A matched-pair sensitivity analysis (n = 28) was performed to reduce differences in age, education, and Mini-Mental State Examination scores. Binary logistic regression was used to examine the association between Aβ-PET positivity and fixation duration in the perceptual AOI.ResultsThe Aβ-PET positive group showed significantly longer fixation duration in the perceptual AOI (p = 0.027, r = 0.296), whereas no significant group differences were observed in the working AOI. Exploratory analyses showed higher fixation count, visit duration, visit count, and saccade count in the perceptual AOI of the Aβ-PET-positive group. Longer fixation duration in the perceptual AOI was independently associated with Aβ positivity (OR per second = 1.18, 95% CI 1.03-1.36, p = 0.021).ConclusionsAβ-PET positivity in MCI was associated with greater perceptual-phase gaze inefficiency during figure copying. Perceptual-phase eye-tracking metrics may serve as potential markers of amyloid-related visuospatial alteration in MCI.
Life course influences on cognitive aging and dementia risk: A mini-forum on the role of socioeconomics, caregiving, and social determinants.
Robinson-Lane SG, Tarraf W, Choi H … +2 more , Antonucci TC, Ajrouch KJ
J Alzheimers Dis · 2026 Jun · PMID 42340314 · Publisher ↗
Abstract loading — click title to view on PubMed.
The effectiveness of psychoeducational interventions for family caregivers of people with dementia in Asia: A systematic review.
Yap EYA, Chia DB, Lee JJ … +3 more , Choo MH, Cheng HK, Shankar R
J Alzheimers Dis · 2026 Jun · PMID 42340312 · Publisher ↗
BackgroundDementia is a growing health challenge in the Asia-Pacific region, where family caregivers experience substantial burden shaped by cultural expectations of filial piety. Psychoeducational interventions are reco...
BackgroundDementia is a growing health challenge in the Asia-Pacific region, where family caregivers experience substantial burden shaped by cultural expectations of filial piety. Psychoeducational interventions are recommended non-pharmacological strategies to support caregivers; however, no systematic review has evaluated their effectiveness specifically within Asian populations. Understanding their effectiveness is critical given cultural factors influencing caregiving experiences in Alzheimer's disease and other dementias.ObjectiveTo synthesize the effectiveness of psychoeducational interventions in reducing caregiver burden among Asian family caregivers of people with dementia, describe intervention characteristics, and identify factors influencing effectiveness.MethodsThis systematic review followed PRISMA 2020 guidelines. CINAHL, Cochrane, Embase, PubMed, PsycINFO, Scopus, and Web of Science were searched for studies published between 1 January 2012 and 1 November 2025. Two investigators independently conducted study selection, quality appraisal using the Joanna Briggs Institute critical appraisal tool, and data extraction. A narrative synthesis was conducted due to study heterogeneity.ResultsTen randomized controlled trials were included. Interventions varied in conceptual theories, delivery mode, format, and duration. Six studies reported significant reductions in caregiver burden. More effective interventions were delivered via telephone, provided individually, and implemented over three months. Some studies also reported improvements in self-efficacy, depression, perceived stress, and distress. None incorporated gender-sensitive approaches in intervention design or evaluation.ConclusionsPsychoeducational interventions show promise in alleviating burden among Asian family caregivers of people with dementia, including those with Alzheimer's disease. Tailoring delivery mode, format, and duration may optimize effectiveness. Future research should include diverse Asian populations and incorporate gender-sensitive approaches.
Functional difficulties, receipt of help, and unmet needs among people with newly diagnosed dementia: Results from the DETERMIND project.
Read S, Brimblecombe N, Hicks B … +3 more , Hu B, King D, Wittenberg R
J Alzheimers Dis · 2026 Jun · PMID 42340309 · Publisher ↗
BackgroundNewly diagnosed people with dementia and Alzheimer's disease may have varying levels of functional difficulties in which help is required. Little is known about how their needs are met, the associations of need...
BackgroundNewly diagnosed people with dementia and Alzheimer's disease may have varying levels of functional difficulties in which help is required. Little is known about how their needs are met, the associations of needs with care dyad background characteristics and how these characteristics are associated with each other.ObjectiveWe investigated the pathways between background characteristics, functional difficulties (need) and receipt of help.MethodsThe sample included 672 newly diagnosed people with dementia and their carers. Four activities of daily living (ADLs), three instrumental activities of daily living (IADLs) and receipt of help in these activities were used to define needs and unmet needs. Receipt of adequate support from health and social care services was also reported. Regression and path models explored the associations with background characteristics.ResultsMost people with dementia had at least one ADL (42%) or IADL (83%) difficulty. Among those who had a difficulty, 50% and 31% had at least one unmet ADL or IADL need, respectively. Support from health and social care services was reported as inadequate by 29%. Many background characteristics (age, gender, education, homeownership, urban-rural location, area deprivation) were associated with receipt of help through functional limitations and/or whether the carer was spouse or coresident.ConclusionsAlthough people newly diagnosed with dementia had fewer ADL than IADL difficulties, unmet need was proportionally higher for ADLs than IADLs. The findings point to possible barriers to receiving help shaped by complex pathways through sociodemographic factors, current levels of functioning and carer characteristics.
Measures used to evaluate psychosocial interventions in dementia care: A narrative review and synthesis.
Brookman R, Christensen J, Maurice OR … +11 more , Aghaei M, Cass A, Monzaviyan S, Shatnawi E, Carter M, Tran J, McIlwain N, Garrido S, Siette J, Strutt P, Harris CB
J Alzheimers Dis · 2026 Jun · PMID 42340306 · Publisher ↗
Psychosocial interventions are widely used in dementia care, yet standardized outcome measurement remains highly variable, and recent frameworks emphasize outcomes prioritized by people living with dementia and their car...
Psychosocial interventions are widely used in dementia care, yet standardized outcome measurement remains highly variable, and recent frameworks emphasize outcomes prioritized by people living with dementia and their care partners. This narrative, measurement-focused review does not appraise or synthesize treatment effects. Instead, it aims to map outcome measures to the International Consortium for Health Outcomes Measurement (ICHOM) dementia set plus an additional carer-wellbeing domain, to organize them into a taxonomy of wellbeing domains that highlights patterns and gaps in measurement practice. Eligible studies included participants with Alzheimer's disease and related dementias, evaluated a psychosocial intervention, and reported standardized pre- and post-intervention outcome measures at short and/or long-term follow-up. A total of 136 studies met inclusion criteria. Interventions encompassed arts and creative therapies, cognitive and reminiscence approaches, education and psychosocial support, physical and movement-based therapies, sensory and relaxation therapies, environmental and daily living support, and animal/robot-assisted programs. Outcome measures clustered on neuropsychiatric symptoms (205 instances) and cognitive functioning (146 instances), with fewer measures of social functioning (22 instances) and health-related quality of life (13 instances). Measurement approaches were highly variable (43 distinct neuropsychiatric measures, 47 cognitive measures, 14 social functioning measures). Outcomes were predominantly assessed using short-term measures, with some long-term follow-up, and few observational in-the-moment measures capturing engagement, enjoyment, reciprocity or mastery. This review presents a taxonomy of outcome measures that highlights the mismatch between current evaluation practices and person-centered psychosocial priorities in dementia care, and guides more purposeful measure selection.
Biomarker affliction classes contribute additively to observed dementia severity and prospective conversion risk.
Royall DR, Palmer RF, Alzheimer's Disease Neuroimaging Initiative
J Alzheimers Dis · 2026 Jun · PMID 42340305 · Publisher ↗
BackgroundDementia is likely to be overdetermined by the independent contributions of its biomarkers, of which Alzheimer's disease (AD)-specific biomarkers are a subset.ObjectiveTo assess the impact of affliction by mult...
BackgroundDementia is likely to be overdetermined by the independent contributions of its biomarkers, of which Alzheimer's disease (AD)-specific biomarkers are a subset.ObjectiveTo assess the impact of affliction by multiple biomarkers on dementia severity.MethodsUsing previously validated algorithms, N = 988 PET (+) subjects of the Alzheimer's Disease Neuroimaging Initiative (ADNI) were assigned to groups "afflicted by" or "resilient against" the effects of central nervous system amyloid-β (Aβ), plasma adipokines, and/or neurodegeneration and tested against Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) and time to dementia conversion.ResultsCDR-SB rose as a function of the number of afflicting biomarkers in both demented and non-demented cases. 327/988 (33.1%) were afflicted by a single biomarker. That biomarker was Aβ in only 19.88% of these PET (+) subjects. 221/988 (22.4%) were afflicted by all three. Only 124/988 (12.6%) were resilient to all three. Affliction by adipokines had the strongest effect (r = 0.33, p < 0.001). Affliction by Aβ was weakest (r = 0.18, p < 0.001). The number of afflicting biomarkers explained 25.2% of CDR variance and significantly impacted conversion risk over 48 months (by χ2 (df = 3) = 56.69, p < 0.001) independently of baseline CDR-SB (by Cox Proportional Hazards Wald χ2 (df = 3) = 26.24, p < 0.001).ConclusionsThe biomarkers that determine dementia severity in PET (+) subjects may ultimately comprise combinations and do not necessarily include Aβ. These findings have implications for A/T/N diagnoses.
Interleukin-6 is associated with white matter hyperintensities and cognition independent of Alzheimer's disease plasma biomarkers-HABS-HD.
Dharmapuri A, Chaudhuri S, Contreras JA … +2 more , Hayes CA, Health and Aging Brain Study (HABS-HD) Study Team *
J Alzheimers Dis · 2026 Jun · PMID 42340301 · Full text
BackgroundChronic inflammation contributes to neurodegeneration and cerebrovascular injury, yet it remains unclear whether inflammatory biomarkers influence white matter hyperintensity (WMH) volume and cognition independ...
BackgroundChronic inflammation contributes to neurodegeneration and cerebrovascular injury, yet it remains unclear whether inflammatory biomarkers influence white matter hyperintensity (WMH) volume and cognition independent of Alzheimer's disease (AD) plasma biomarkers.ObjectiveThis study examined whether inflammatory biomarkers were associated with WMH volume and multidomain cognitive performance independent of AD plasma biomarkers, and whether WMH volume mediated associations between IL-6 and cognition.MethodsUsing data from 1806 participants in the Health and Aging Brain Study-Health Disparities (HABS-HD), we examined associations between log transformed plasma inflammatory biomarkers (IL-10, TNF-α, IL-6, and IL-5) and WMH volume and cognitive performance (memory, executive function, processing speed, language). Multivariable linear regression models adjusted for demographic and vascular risk factors were repeated with additional adjustment for AD biomarkers (p-Tau181, NfL, total tau, Aβ). Mediation analyses were included to test whether WMH meditated the association between IL-6 and cognitive domains.ResultsHigher IL-6 levels were consistently associated with increased WMH volume in base and AD-adjusted regression models. Increased levels of IL-6 were also associated with poorer performance in all cognitive domains, but these associations did not survive multiple comparisons correction. WMH partially mediated the association between IL-6 and memory (23%) and processing speed (19%).ConclusionsElevated IL-6 is independently linked to cerebrovascular injury and poorer cognition beyond classical AD biomarkers, supporting a vascular-inflammatory pathway distinct from amyloid and tau pathology. These findings underscore the importance of integrating inflammatory and neurodegenerative markers to elucidate heterogeneous mechanisms of brain aging across diverse populations.
A needed revision for the definition of subjective cognitive decline.
Kremen WS
J Alzheimers Dis · 2026 Jun · PMID 42340254 · Publisher ↗
Subjective cognitive decline (SCD) as defined by the SCD-initiative (2014/2020) is now nearly universally accepted. In this framework, conditions characterized by objective cognitive impairment are distinct from SCD, and...
Subjective cognitive decline (SCD) as defined by the SCD-initiative (2014/2020) is now nearly universally accepted. In this framework, conditions characterized by objective cognitive impairment are distinct from SCD, and SCD is not a diagnostic category. The criteria prevent the straightforward linguistic expression, 'subjective cognitive decline', from being applied to someone with objective cognitive impairment. However, individuals with objective impairment can, of course, experience of subjective decline. The definition thus operates as a quasi-diagnostic category, precluding description of subjective experience for some individuals. Here I propose a simple solution: preclinical and clinical SCD (P-SCD/C-SCD) for objectively unimpaired and impaired individuals, respectively.
When caring becomes a challenge: A path analysis of coping in Alzheimer's disease caregiving.
Monteiro AMF, Lima Nogueira MM, Barbeito Lacerda I … +2 more , Belfort T, Dourado MCN
J Alzheimers Dis · 2026 Jun · PMID 42337855 · Publisher ↗
BackgroundNeuropsychiatric symptoms (NPS) affect most individuals with Alzheimer's disease (AD) and are among the most burdensome aspects of the condition, negatively influencing caregivers' mental health, burden, and qu...
BackgroundNeuropsychiatric symptoms (NPS) affect most individuals with Alzheimer's disease (AD) and are among the most burdensome aspects of the condition, negatively influencing caregivers' mental health, burden, and quality of care.ObjectiveGiven the scarcity of studies examining caregivers' characteristics and NPS simultaneously, this study investigated how sociodemographic and clinical factors relate to different coping strategies, and whether NPS moderate these associations. Path analysis was used to capture direct and conditional effects.MethodsA cross-sectional study of 176 caregiver-patient dyads assessed coping, burden, mood, and NPS. Path analysis examined the effects of caregiver education, burden, depressive symptoms, and sex on coping, with NPS as a moderator.ResultsHigher education predicted greater use of problem-focused (β = 0.43, p < 0.001) and dysfunctional coping (β = 0.22, p < 0.01). Burden was negatively linked to emotion-focused coping (β = -0.17, p < 0.05). NPS moderated the burden-problem-focused coping link (β = -0.16, p < 0.05).ConclusionsEducation plays a central role in shaping how caregivers cope with care demands. NPS moderated the relationship between caregiver burden and problem-focused coping, with limited influence on other strategies. These findings underscore the importance of considering both caregiver characteristics and patient-related factors when developing interventions, highlighting the need for personalized approaches to improve caregiver well-being and care outcomes.
A novel antibody against CD300c ameliorates cognitive deficits and reduces pathology in the late-stage of APP/PS1 mouse model.
Lee S, Choi BJ, Park MH … +6 more , Park S, Kim J, Jin HK, Shim H, Jeon JW, Bae JS
J Alzheimers Dis · 2026 Jun · PMID 42337854 · Publisher ↗
BackgroundA major pathological hallmark of Alzheimer's disease (AD), the most common cause of dementia, is the accumulation of amyloid-β (Aβ) plaques. However, currently approved therapeutic agents fail to fundamentally...
BackgroundA major pathological hallmark of Alzheimer's disease (AD), the most common cause of dementia, is the accumulation of amyloid-β (Aβ) plaques. However, currently approved therapeutic agents fail to fundamentally halt disease progression and have limitations in terms of efficacy, sustainability, and safety. CD300c is an immunoregulatory molecule that modulates monocyte differentiation and activates macrophages. We recently developed a fully human anti-CD300c antibody, CB201, demonstrating its therapeutic potential in early and late 5xFAD mice.ObjectiveThis study investigated the efficacy of CB201 in late-stage AD using the APP/PS1 transgenic mouse model. We analyzed the effects of administering CB201 on changes in memory and cognitive function and Aβ and tau protein accumulation in the brain.MethodsTo assess long- and short-term memory improvements, behavioral tests were conducted using the Morris water maze and fear conditioning. Immunostaining was performed to quantify changes in Aβ and tau accumulation.ResultsCB201-treated late-stage AD mice demonstrated improved cognitive performance and memory, comparable to wild-type controls. Histopathological analysis further revealed that CB201 treatment reduced Aβ and tau accumulation.ConclusionsCB201 exerts significant therapeutic effects on functional impairments and pathological alterations in late-stage AD. These results confirm CB201 as a potential immunotherapeutic for the treatment of AD.
Vitamin D in Alzheimer's disease: Neuroinflammatory, metabolic, and clinical implications.
Kashif M, Ho MH, Pandurangan AK … +3 more , Waseem M, Majumder D, Chou SY
J Alzheimers Dis · 2026 Jun · PMID 42334178 · Publisher ↗
BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. Beyond amyloid-β and tau pathology, accumulating evidence indicates that chronic neuroinflammati...
BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. Beyond amyloid-β and tau pathology, accumulating evidence indicates that chronic neuroinflammation, oxidative stress, mitochondrial dysfunction, disrupted calcium homeostasis, and diabetes are critically contributing to disease onset and progression, underscoring the need to identify modulatory factors that influence multiple pathogenic pathways.ObjectiveThis review evaluates the role of vitamin D in modulating cognitive function and its association with the pathophysiology of AD.MethodsThis narrative review examines the connection between vitamin D and cognitive and neurological outcomes by integrating findings from preclinical and clinical studies. Relevant literature was identified through a PubMed search, restricted to English language publications available up to 2025.ResultsVitamin D, a secosteroid hormone traditionally associated with bone metabolism, has emerged as a potential neuroprotective factor in the aging brain. Vitamin D receptors are widely expressed in neurons and glial cells, and vitamin D readily crosses the blood-brain barrier. Despite increasing evidence linking vitamin D deficiency to AD, its mechanistic roles in neuroinflammation and metabolic dysfunction, as well as its translational relevance, remain incompletely understood. Experimental and clinical studies suggest that vitamin D modulates amyloid metabolism, microglial activation, inflammatory signaling, redox balance, mitochondrial function, synaptic integrity, and regulates insulin resistance.ConclusionsIn this review, we integrate evidence from molecular, cellular, animal, and human studies to examine the role of vitamin D in AD. Finally, we highlight current limitations and knowledge gaps and outline future directions for clinical and translational research.
Prevalence and determinants of polypharmacy and its association with cognitive and functional performance in community-dwelling older adults: A population-based study.
Freire-Flores D, Ramos M, Burgos H … +1 more , Carvallo C
J Alzheimers Dis · 2026 Jun · PMID 42334176 · Publisher ↗
BackgroundPopulation aging is accompanied by increasing multimorbidity and medication exposure, raising concerns regarding the role of polypharmacy as a potential modifiable risk factor for cognitive decline and Alzheime...
BackgroundPopulation aging is accompanied by increasing multimorbidity and medication exposure, raising concerns regarding the role of polypharmacy as a potential modifiable risk factor for cognitive decline and Alzheimer's disease. However, polypharmacy is a heterogeneous construct, and its cognitive impact may depend more on regimen complexity and pharmacological burden than on medication count alone.ObjectiveTo estimate the prevalence and determinants of polypharmacy and to examine its association with functional status and cognitive performance in community-dwelling older adults from southern Chile.MethodsA cross-sectional study was conducted between 2023 and 2025 including 848 adults aged ≥60 years from four provinces in the Los Lagos Region. Sociodemographic, clinical, and psychosocial data were collected through structured interviews and standardized assessments. Functional status was evaluated using EFAM-Chile, Barthel, and Pfeffer scales, and Cognitive performance and functional status were assessed using the Preventive Medicine Examination for Older Adults (EFAM-Chile). Polypharmacy was defined as the concurrent use of ≥5 medications, including prescribed and over-the-counter drugs. Regimen complexity and anticholinergic/sedative burden were quantified using the Medication Regimen Complexity Index (MRCI) and the Drug Burden Index (DBI).ResultsPolypharmacy was associated with better functional and cognitive scores in unadjusted analyses (p < 0.05), although these associations were not independent after adjustment. Multimorbidity was the strongest predictor of medication count. Despite greater medication exposure, MRCI and DBI values remained within low-to-moderate ranges, indicating limited pharmacological burden relevant to cognitive vulnerability. These findings may be explained by reverse causation or by confounding related to health statusConclusionsIn this population, polypharmacy was not associated with cognitive screening outcomes, although the absence of detailed neuropsychological assessment limits conclusions regarding cognitive impairment or dementia risk and may reflect optimized management of chronic conditions. Qualitative pharmacological indices may improve the identification of medication-related cognitive risk in aging populations.
Monitoring Alzheimer's disease-related fluid microenvironment changes using magnetic resonance-based electrical conductivity imaging.
Choi BK, Park JA, Kim TH … +5 more , Kim HC, Ko IO, Oh TI, Kim JW, Kim HJ
J Alzheimers Dis · 2026 Jun · PMID 42334154 · Publisher ↗
Cerebrospinal fluid (CSF) status is an indicator of pathological feature associated with metabolic waste clearance dysfunction in Alzheimer's disease (AD) progression. Magnetic resonance-based conductivity imaging provid...
Cerebrospinal fluid (CSF) status is an indicator of pathological feature associated with metabolic waste clearance dysfunction in Alzheimer's disease (AD) progression. Magnetic resonance-based conductivity imaging provides novel contrast sensitive to ion concentration, mobility, and microstructural changes. We applied conductivity imaging to 5xFAD mice and age-matched wild-type controls using 9.4 T MRI, measuring regional conductivity in ventricular CSF, caudate putamen, cerebral cortex, thalamus, and hippocampus. AD mice showed ventricular enlargement with significantly elevated CSF conductivity, and increased hippocampal conductivity consistent with AD involvement, but no changes in other regions. These findings suggest conductivity imaging as a marker of fluid microenvironmental changes in AD.
Corrigendum to "Aluminum involvement in the progression of Alzheimer's Disease".
J Alzheimers Dis · 2026 Jun · PMID 42334143 · Publisher ↗
Abstract loading — click title to view on PubMed.
Pilot feasibility, acceptability, and tolerability of researcher-delivered apolipoprotein E () disclosure via videoconferencing in Australian adults at-risk of dementia.
Rosenich E, Chauhan S, Haeusler R … +6 more , Keriakes M, Cummins H, Olver H, Bransby L, Maruff P, Lim YY
J Alzheimers Dis · 2026 Jun · PMID 42316930 · Publisher ↗
BackgroundIn Australia, access to Alzheimer's disease (AD) therapeutics requires apolipoprotein E () genotype testing and disclosure, yet the feasibility, acceptability and tolerability of disclosure in an Australian co...
BackgroundIn Australia, access to Alzheimer's disease (AD) therapeutics requires apolipoprotein E () genotype testing and disclosure, yet the feasibility, acceptability and tolerability of disclosure in an Australian context remains unknown.ObjectiveThis pilot study evaluated a researcher-delivered, videoconferencing-based disclosure protocol in cognitively unimpaired (CU) Australian adults with dementia family history.MethodsThe DISCLOSE- protocol, informed by prior expert approaches and Australian consumer preferences, was piloted in fifteen CU adults aged 40-70 (8 ε4 carriers, 7 non-carriers). The protocol comprised 7 online sessions, including mood/suicide risk assessment, education, and psychological readiness evaluation. genotype was disclosed 1:1 via videoconferencing using a standardized interaction procedure. Existing data and online questionnaires assessed participant characteristics and outcomes pre- and post-disclosure. Paired-samples t-tests examined within-group mood changes, and independent-samples t-tests compared post-disclosure test-/event-related distress between carriers and non-carriers.ResultsAll participants (M age = 60.8 (±6.4), 60% female) completed the pilot, and no adverse events occurred. Baseline mood was equivalent across groups. Anxiety decreased post-disclosure in both ε4 carriers and non-carriers. Depressive symptoms increased slightly but not significantly in ε4 carriers and remained sub-threshold. Test-related distress was moderately higher in ε4 carriers post-disclosure.ConclusionsResearcher-delivered and remote disclosure via videoconferencing resulted in no attrition nor clinically-significant short-term psychological distress, with pilot data providing preliminary evidence of feasibility, acceptability and tolerability in this cohort. Findings will inform the development and implementation of culturally-appropriate and scalable disclosure protocols in research and clinical settings to facilitate delivery of anti-Aβ therapies in Australia.
and clonal hematopoiesis do not modify murine tauopathy.
Gaebel L, Gerhardt T, Khamhoung A … +9 more , Huynh P, Heiser M, Brisnovali NF, Jacob W, Yates AG, Douglas A, Fidler T, Goedeke L, McAlpine CS
J Alzheimers Dis · 2026 Jun · PMID 42316878 · Publisher ↗
BackgroundClonal hematopoiesis (CH) increases with age and elevates the risk of numerous age-associated diseases. However, the association between CH and neurodegenerative diseases has remained unclear.ObjectiveWe tested...
BackgroundClonal hematopoiesis (CH) increases with age and elevates the risk of numerous age-associated diseases. However, the association between CH and neurodegenerative diseases has remained unclear.ObjectiveWe tested the association between the presence of CH and tauopathy in a murine model.MethodsWe established novel models of loss-of-function and gain-of-function (V617F) CH in CD45.1-expressing tauopathy mice using unconditioned bone marrow (BM) cell transfer, thereby maintaining brain integrity, clonal expansion, and enabling mutant cell tracking.ResultsIn CD45.1- mice, cells (CD45.2) started at a fraction of <2% and clonally expanded in all BM cavities and the blood over 5 months. mutant and WT immune cells, however, displayed equivalently low capacity to infiltrate the brain of mice even with advanced tau deposition. While mutant microglia displayed elevated IL1-β production, they comprised a small fraction (3.49 ± 1.35%) relative to the high frequency of mutant monocytes in the blood (26.36 ± 4.33%) of aged CD45.1- mice after clonal expansion. cells (CD45.2) also expanded clonally in the BM and blood over time and had a modestly increased capacity to infiltrate the brain of aged CD45.1- mice but their proportion among brain microglia remained low (1.12 ± 0.28%) relative to blood monocytes (28.91 ± 4.66%). Critically, or CH did not alter tau accumulation in the hippocampus or cortex, nor did they influence brain atrophy.ConclusionsOur findings suggest that CH mutant cells do not influx the murine tauopathy brain in large proportions and that CH does not modify neurodegeneration or tau accumulation in mice.
The evolving burden of early-onset Alzheimer's disease and other dementias in BRICS countries: Insights from the Global Burden of Disease Study 2023 and projections to 2035.
Yang L, Zeng J, Huang L … +1 more , Li L
J Alzheimers Dis · 2026 Jun · PMID 42312433 · Publisher ↗
BackgroundThe burden of early-onset Alzheimer's disease and other dementias (EOAD) in BRICS nations (Brazil, Russia, India, China, South Africa, Egypt, Ethiopia, Iran, Saudi Arabia, the United Arab Emirates, and Indonesi...
BackgroundThe burden of early-onset Alzheimer's disease and other dementias (EOAD) in BRICS nations (Brazil, Russia, India, China, South Africa, Egypt, Ethiopia, Iran, Saudi Arabia, the United Arab Emirates, and Indonesia) is poorly characterized.ObjectiveOur aims are to characterize national trends, identify high-burden populations, quantify sex- and risk factor-specific burdens, and inform targeted prevention and age-inclusive healthcare strategies in these key nations.MethodsUsing data from the Global Burden of Disease Study (GBD) 2023, we analyzed EOAD (ages 40-64) across BRICS countries from 1990-2023, employing decomposition, Joinpoint regression, and Bayesian Age-Period-Cohort modeling to project trends to 2035.ResultsPrevalent cases increased in all nations, led by China. Age-standardized incidence rose in China (average annual percentage change 0.461%) but declined in India and Iran. Females consistently bore a higher burden. Ambient particulate matter drove substantial disability-adjusted life years in Iran (74.43/100,000) and Saudi Arabia, while household air pollution was key in Ethiopia and India. Projections indicate divergence by 2035, with Russia's incidence rising to 56.22 and Saudi Arabia's prevalence falling to 160.10 per 100,000.ConclusionsEOAD burden in BRICS is heterogeneous, driven by aging, sex, and modifiable risks, necessitating tailored public health strategies.
Role of suvorexant in Alzheimer's disease: Targeting sleep, orexin signaling, and disease pathophysiology.
Ahmed Abbasi A, Norouziyan F, Moradikor N
J Alzheimers Dis · 2026 Jun · PMID 42312432 · Publisher ↗
The defining features of Alzheimer's disease (AD) include neurodegeneration, a decline in cognition, and tau and amyloid-β protein pathologies. Sleep problems affect many individuals with AD and could be an aggravating f...
The defining features of Alzheimer's disease (AD) include neurodegeneration, a decline in cognition, and tau and amyloid-β protein pathologies. Sleep problems affect many individuals with AD and could be an aggravating factor in the disease because it creates a barrier to the glymphatic system's ability to clear neurotoxic proteins, disrupt the plasticity of synapses, and increase neuroinflammation. Suvorexant, which works as a dual orexin receptor antagonist, has proven effective in the management of sleep problems by fine-tuning the orexin system, which regulates arousal. Preliminary studies indicate that, in addition to improving sleep, Suvorexant could potentially help in the reduction of amyloid and tau buildup, as well as the improvement of synaptic activity and reduction of neuroinflammation. Recent clinical studies show improvements in sleep quality among older adults, in addition to safety and efficacy, and suggest increasing cognitive functioning in mild cognitive impairment and early AD. This review summarizes the existing research on the potential of Suvorexant as a therapeutic to address the mechanisms of orexin signaling in AD, as well as the sleep-targeted interventions to address the symptoms and modify the disease to improve cognitive functioning. We also emphasize future research directions such as cognitive outcomes over extended periods, potential optimal dosing, and combinatory strategies with lifestyle and/or medication therapies. This review will discuss the current evidence regarding the therapeutic effects of suvorexant and orexin signaling in AD.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe